Please login to the form below

Not currently logged in
Email:
Password:

New board member for Oxford Genome Sciences

Cancer-focused, UK-based genomics company Oxford Genome Sciences has asked Christopher Hibberd to join its board of directors.

Cancer-focused, UK-based genomics company Oxford Genome Sciences (OGeS) has asked Christopher Hibberd to join its board of directors.

The addition of Hibberd is due to his experience in business strategy and corporate development, specifically for the identification of strategic business opportunities in the areas of mergers, acquisitions, partnerships and alliances.

Hibberd is currently working as CEO of Astute Medical and prior to that worked for 10 years at Biosite, as senior vice-president of corporate development. OGeS partners with Biosite in the development of diagnostics for cancer based on OGeS' OGAP protein database.

Prior to Biosite, Hibberd was manager at Boston Consulting Group and was responsible for leading international consultants and client case teams in developing and implementing value-creating strategies for businesses in a variety of industry sectors.

Dr Christian Rohlff, CEO of OGeS, said: "I am very pleased to welcome Christopher to OGeS' Board of Directors. I am confident that his broad expertise will be valuable to support OGeS' corporate development at a time when we are transitioning from target discovery to building our own product pipeline of therapeutic antibodies."

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics